TrialAmerican journal of hematology2014

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.

Carlo Gambacorti-Passerini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.